AU565 Cells

The AU565 cell line is derived from a human breast carcinoma and is classified as HER2-positive, making it a valuable model for studying HER2-targeted therapies such as trastuzumab (TZM). These cells are widely used to investigate breast cancer behaviors, particularly regarding targeted drug delivery and metastatic processes. Research utilizing AU565 cells has shown that they exhibit significant HER2 expression at the plasma membrane, facilitating studies on the binding efficiency and internalization of anti-HER2 monoclonal antibodies like TZM. AU565 cells display efficient TZM binding at the membrane with subsequent accumulation in intracellular compartments, providing insights into the endocytic and trafficking mechanisms involved in TZM uptake and retention within tumor cells. This unique behavior makes AU565 a distinctive model compared to other HER2-positive cell lines and supports its use in exploring drug efficacy and cell membrane dynamics.
AU565 cells also serve as a model for studying metastatic behavior, specifically transendothelial migration, which is a critical step in cancer metastasis. As a weakly invasive cell line, AU565’s ability to migrate across endothelial cell layers is highly dependent on focal adhesion kinase (FAK) signaling, which facilitates interactions with the extracellular matrix and endothelial cells during migration. Inhibiting FAK activity in AU565 cells has been shown to reduce their migration rates, highlighting FAK’s role in cell motility and suggesting its potential as a therapeutic target to limit metastatic progression. Additionally, AU565 cells exhibit responses to variations within the tumor microenvironment, such as differences in collagen density, which can impact drug delivery efficacy and resistance. These characteristics make AU565 cells a powerful model for studying HER2-targeted therapies and the influences of the tumor microenvironment on treatment outcomes.